TMO
Thermo Fisher Scientific Inc.
Healthcare · Diagnostics & Research · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- TMO scores 63.4/100 primarily because its dividend (18.8/20) and financial health (16.0/20) sub-scores are genuinely strong, pulling the composite score into positive territory despite weaknesses elsewhere.
- The profitability sub-score of 14.8/20 confirms the 10-K filing shows above-average margins and returns on assets, validating a fundamentally sound operating model that justifies a mid-range composite score.
- The model assigned a Research Candidate label with Medium risk, consistent with a large, cash-generative company that does not present extreme leverage or coverage concerns but also does not exhibit the growth acceleration required for a higher ranking.
Why Not Higher
- The theme sub-score of 0.0/20 is a significant score ceiling — had the filing demonstrated exposure to four or more identifiable macro themes, this sub-score could have added up to 20 points to the composite, potentially pushing the total well above 70.
- The growth sub-score of 10.0/20 reflects weak year-over-year metrics in the FY2025 10-K; materially stronger revenue and EPS growth would have raised this sub-score and lifted the overall model score substantially.
Data Confidence
10 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Thermo Fisher Scientific Inc. is a global leader in life sciences instrumentation, analytical tools, reagents, consumables, and services, serving pharmaceutical and biotech customers, academic research institutions, hospitals, and government agencies. The company's broad portfolio spans laboratory equipment, clinical diagnostics, bioproduction, and specialty chemicals, making it a critical supplier across the drug discovery, development, and manufacturing value chain. Its scale and diversification across these end markets underpin its generally stable revenue base. The model scored TMO 63.4/100 under the standard scoring framework, reflecting a mixed but genuinely solid profile: strong dividend sub-scores (18.8/20) and financial health (16.0/20) anchor the rating, while a zero theme score (0.0/20) — indicating no detected macro thematic tailwinds in the filing data — and a soft growth sub-score (10.0/20) constrain the overall result. The momentum sub-score of 11.0/20 suggests quarterly fundamental improvement has been modest rather than accelerating. The key research tradeoff here is that TMO scores best as a dividend income research candidate (74.4 profile score) rather than an aggressive growth play (52.9), reflecting a mature, cash-generative business with measured fundamental momentum rather than a high-velocity growth story.
Plain English
Thermo Fisher Scientific makes the tools, machines, and chemicals that scientists use in labs — think of them as the hardware store for the life sciences world. A model score of 63.4 out of 100 means the research model sees genuine strengths, particularly in dividend quality and financial health, but also real limitations in growth and thematic momentum. The Medium risk rating reflects that this is a large, established business with manageable leverage and solid cash flow, not a speculative or early-stage operation. For a researcher focused on income-oriented positions, TMO's filing data looks more compelling than it would for someone hunting rapid earnings expansion.
Bull Case vs. Bear Case
Bull Case
- The dividend sub-score of 18.8/20 is the model's highest sub-score and reflects strong free cash flow coverage of dividends, a consistent dividend per share streak, and meaningful DPS growth over the measurement period, supporting the income thesis.
- The financial health sub-score of 16.0/20 indicates that leverage ratios and interest coverage metrics derived from the 10-K are at levels the model considers manageable, suggesting the balance sheet is not a near-term vulnerability.
- The profitability sub-score of 14.8/20 reflects solid net margins, operating margins, and return on assets as reported in the FY2025 10-K filing, consistent with a business that retains meaningful pricing power across its instrumentation and consumables segments.
Bear Case
- The growth sub-score of 10.0/20 is notably weak, indicating that year-over-year revenue, net income, and EPS growth figures from the 10-K filing were insufficient to score well, suggesting the company's top- and bottom-line expansion has materially decelerated.
- The theme sub-score of 0.0/20 means the model detected no macro thematic tailwinds in the SEC filing, which limits the forward-looking narrative appeal of this name compared to peers exposed to AI-driven drug discovery, GLP-1 manufacturing, or other identifiable structural growth themes.
- The momentum sub-score of 11.0/20 reflects only modest sequential improvement in quarterly revenue, earnings, and margins, indicating that fundamental re-acceleration is not yet visible in the filing data.
What Could Change the Picture
Bullish Triggers
- Evidence in a subsequent 10-K or quarterly filing of re-accelerating organic revenue and EPS growth — particularly in the Life Sciences Solutions or Bioproduction segments — would raise the growth sub-score and improve the overall research view.
- Detection of macro thematic exposure (such as GLP-1 biologics manufacturing, AI-assisted drug discovery tooling, or pandemic preparedness infrastructure) in a future filing update would move the theme sub-score above zero and potentially add meaningful points to the composite.
Bearish Triggers
- A deterioration in the financial health sub-score driven by rising leverage ratios or declining interest coverage — for example from a large debt-financed acquisition — would weaken one of the model's key anchors for this name.
- Any reduction in free cash flow coverage of dividends or an interruption in the DPS growth streak, as captured in the dividend sub-score inputs, would undermine the primary reason the income profile scores well (74.4) and could prompt a reassessment of the research label.
Red Flags
- The combination of a low growth sub-score (10.0/20) and flat momentum (11.0/20) may indicate that post-pandemic COVID-related revenue tailwinds have meaningfully unwound, and the underlying organic growth rate of the business has not yet returned to historical norms.
Risk Profile
Medium RiskThe Medium risk rating reflects that TMO's 10-K filing shows manageable leverage and solid interest coverage, making balance sheet distress an unlikely near-term scenario, but the decelerating growth and absent thematic momentum mean fundamental outcomes are not without uncertainty. The risk profile is consistent with a mature, large-cap industrial-scale life sciences company navigating a post-peak revenue cycle rather than a structurally impaired or highly speculative business.
Key Catalysts to Watch
The key fundamental catalyst to monitor is whether TMO's organic revenue growth rate, as reported in future SEC filings, demonstrates a credible recovery from the low growth sub-score recorded in FY2025, particularly in its biopharma services and instrument upgrade cycles. Equally important is any emergence of thematic alignment — such as expanded exposure to biologic drug manufacturing capacity buildout — that would register in the model's theme scoring and support a higher composite score.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.